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Although anti-tumor necrosis factor (TNF) therapy has revo- 
lutionised the management of spondyloarthritis (SpA), 20–30% 
of SpA patients discontinue biological treatment because they 
fail to respond or their response is inadequate, and 10–20% 
stop because of a lack or loss of efﬁcacy or the onset of 
adverse events. Published data show that anti-TNF drugs in 
are highly effective in patients with ankylosing spondylitis, and 
associated with a higher drug persistence rate. Furthermore, 
studies suggest considering a switch to another anti-TNF drug 
if a ﬁrst anti-TNF agent is discontinued because of loss of 
efﬁcacy or adverse events.
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A nkylosing spondylitis (AS), a prototype of the spondyloar-thritis (SpA) family, is a chronic, progressive, inflammatory 
disease of the axial skeleton that mainly involves the spine and 
sacroiliac joints [1] but may also affect other sites such as the 
anterior joints of the chest wall [2]. It can lead to severe chronic 
pain and discomfort [1-3], and treatment should be started as 
early as possible to prevent skeletal deformity and physical dis-
ability [4].
Although anti-tumor necrosis factor (anti-TNF) therapy 
has revolutionised the management of spondyloarthritis (SpA), 
20–30% of SpA patients discontinue biological treatment 
because they fail to respond or their response is inadequate [5], 
and 10–20% stop because of a lack or loss of efficacy (LOE) or 
the onset of adverse events [6].
Delaunay and colleagues [7] 
first reported that switching to 
another anti-TNF drug may be 
useful in SpA patients who are 
unresponsive to, or cannot toler-
ate, a first anti-TNF drug. Subsequent prospective observational 
studies have confirmed the safety and efficacy of switching from 
one anti-TNF drug to another [8,9]. As anti-TNF drugs are 
structurally different and have different mechanisms of action, 
unsuccessful treatment with one does not preclude a response 
to another [10].
The efficacy of switching anti-TNF drugs has been evalu-
ated in some large studies of patients with AS or axial SpA. The 
RAPID-axSpA trial [11] found that, if the initial discontinua-
tion was for reasons other than primary failure, 40% of patients 
could be successfully treated with anti-TNF drugs for about 3 
months before requiring certolizumab pegol treatment; how-
ever, the subgroup analysis has not yet been published [11]. One 
open-label trial showed that 26.1% of 1250 AS patients treated 
with adalimumab had previously received etanercept and/or 
infliximab, and that these patients had worse Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) 50 and Assessment 
of Spondyloarthritis International Society (ASAS) 40 responses. 
A response with partial remissions was obtained after the switch, 
compared to patients treated with adalimumab as a first-line 
treatment [12].  
LITERATURE SEARCH
A search was conducted using the PubMed databases from 1999 
to 2016 using the keywords: “ankylosing Spondylitis,” “spondy-
loarthritis,” and “anti-TNF drugs” and coupled with “failure.” 
To be included in this review, the study had to be a randomized 
control trial (RCT), systematic review, or observational study 
(i.e., cross-sectional, non-interventional case-control, or cohort 
studies) evaluating AS treatment after the first anti-TNF failure. 
REGISTRY DATA
Compared to RCTs, drug prescription and use in the real world 
vary and involve many more people. The treatment compli-
ance and health expectations of 
real-world patients are different 
from those participating in RCTs 
[13]; consequently, the biological 
drug sequences used in normal 
clinical practice (e.g., a switch to 
a third or fourth drug, and then a return to a previously used 
drug) are also different from those used in RCTs. Moreover, the 
effectiveness and safety anti-TNF drug switching and drug sur-
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vival rates have never been studied in RCTs. There is an increas-
ing need to use registry data in analyses of the cost effectiveness 
of switching from one drug to another [14]. 
The national Danish and Norwegian registries have provided 
data relating to AS patients who switched to another anti-TNF 
drug [15,16]. The DANBIO [15] registry analysed data relat-
ing to 432 patients who switched to a second, and 137 patients 
who switched to a third anti-TNF drug, and compared the 
finding with those relating to 1004 non-switchers. Response 
and drug survival rates were lower among the switchers. The 
NORDMARD registry [16] evaluated the effectiveness of a 
second anti-TNF drug in 77 switchers with AS and found that 
switching to a second anti-TNF drug is useful in everyday 
clinical practice even though overall 
effectiveness is lower [Table 1]. 
Fifteen percent of the AS patients 
in the Norwegian registry and 30% 
of those in the Danish registry 
switched to a second anti-TNF drug over a period of 8–9 years, 
and similar switching frequencies (13–15%) have been reported 
in observational studies of 100 AS patients [17,18]. The median 
baseline BASDAI values of the patients in the national registries 
were similar, but the switchers included a higher percentage of 
women, patients with a shorter duration of disease and symp-
toms, and patients with higher disease activity and functional 
indices [13,14] Furthermore, the national registries and obser-
vational studies included relatively large numbers of patients 
switching anti-TNF drugs, but no data are available concerning 
individual drug treatment outcomes.
Among the switchers, the effects of the first and second 
anti-TNF drug on disease activity (BASDAI) and response rates 
(BASDAI-50) were similar during the 1 year follow-up period, 
but there was a higher rate of patients achieving BASDAI-50 than 
that reported by other investigators [13,14]. One study found no 
difference between the anti-TNF 
drugs used during the switch, and a 
Spanish study of SpA patients found 
no difference in drug survival rates 
[19]. A review of the literature indi-
cates that 30% of SpA patients starting anti-TNF therapy switch 
to a second anti-TNF drug, that there is no difference in drug 
survival between the first, second, and third anti-TNF drug, and 
that the main reason for switching is LOE. Furthermore, the 
switchers were more frequently women, had higher BASDAI val-
ues, a higher erythrocyte sedimentation rate, and higher pain and 
global status visual analogue scale values than non-switchers [20].
Data concerning AS patients treated with at least one anti-
TNF drug between November 2005 and November 2013 showed 
that switchers were older than non-switchers at the time of start-
ing the first anti-TNF drug. The improvement in BASDAI were 
similar in both groups, but switchers had lower response rates to 
the first and second anti-TNF drugs than the non-switchers [21].
IMMUNOGENICITY
Secondary LOE can be explained by the unique chemical struc-
ture of the anti-TNF drugs [22]. The chimeric monoclonal anti-
body (infliximab) induces the production of anti-drug antibod-
ies more intensively than humanised antibodies (adalimumab 
and golimumab) and the receptor fusion protein, etanercept 
[Figure 1]. One study found anti-drug antibodies in 25.9% of 
SpA patients, 81.8% of whom were found in the patients treated 
with infliximab, 18.2% in these in treatment with adalimumab, 
and none in these treated with etanercept [23]. 
As concomitant treatment with methotrexate or other 
immunosuppressive drugs reduces the production of these anti-
bodies in patients with rheumatoid arthritis (RA) and because 
these drugs are usually not indicated for patients with axial SpA, 
evaluating anti-drug antibody levels in AS patients experienc-
ing LOE may help when making drug switching decisions. A 
meta-analysis of the presence and effects of anti-drug antibod-
ies in patients with different inflammatory diseases (RA, SpA, 
and inflammatory bowel disease) found that drug response was 
worse in the presence of serum anti-drug antibodies, and that 
Of spondyloarthritis patients, 10–20% 
stop anti-tumor necrosis factor therapy 
because of a lack or loss of eﬃcacy  
or the onset of adverse events
Table 1. Frequency of switcher in registry data
Registry Frequency References
DANBIO 432 patients Ann Rheum Dis 2013; 72: 114–55
NORDMARD 77 patients Ann Rheum Dis 2011; 70: 157–63
NORWEGIAN 50% Rheumatology 2011; 50: 714–20
DANISH 30% Rheumatology 2011; 50: 714–20
A
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2012 confirmed the effectiveness of these drugs as first or sec-
ond line, but the baseline presence of enthesitis, psoriasis or 
low CRP levels led to a lower probability of obtaining partial 
remission [30].
The data from observational studies and clinical practice are 
conflicting but suggest that, although there are no published gui-
delines suggesting which is the best strategy to adopt after a first 
anti-TNF failure, switching from one TNF inhibitor to another 
has become common practice 
in patients who fail their initial 
treatment. As all these drugs 
have a similar mechanism of 
action, it is difficult to explain why patients may respond to one 
and not another. Suggested reasons include differential bioavai-
lability, differences in the stability of the drug/TNF complex, the 
development of anti-drug antibodies, and possible differences 
in patient adherence to therapy. The most frequent reason for 
discontinuing is lack of efficacy but, regardless of the reason and 
the sequence of drugs administered, disease activity is reduced 
after switching. Survival on the second biological therapy is lon-
ger than on the first, but shorter than the survival on treatment 
of non-switchers. AS patients can be successfully treated with a 
second TNF antagonist. 
LIMITATIONS
The main limitation of this review was that we evaluated only the 
switching among anti-TNF drugs without considering the new 
therapy with anti-interleukin (IL)-12/23 and anti-IL-17 drugs. 
CONCLUSIONS
Published data primarily suggest that anti-TNF drugs are 
highly effective in AS cohorts and can be associated with a high 
drug retention rate. They also suggest considering the positive 
effects of switching to another anti-TNF drug after the discon-
tinuation of a first because of LOE over time or the occurrence 
of adverse events. 
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the effect of anti-drug antibodies on anti-TNF drug responses 
was higher in the AS and SpA patients than in those with other 
diseases [24].
RETENTION RATES AND PREDICTIVE FACTORS
In a large cohort of 1250 patients with active AS, 1159 patients 
(92.7%) completed 12 weeks of treatment with adalimumab and, 
at the end of the treatment period, 57.2% had achieved BASDAI 
50, 53.7% ASAS40, and 27.7% 
ASAS partial remission. These 
outcomes were strongly associ-
ated with a younger age, higher 
C-reactive protein (CRP) levels, human leukocyte antigen B27 
positivity, and anti-TNF drug naïvety [25].
Another study found that the overall 10 year retention rate 
of a first-line anti-TNF drug was about 23%, and significantly 
higher in SpA than in RA patients. The drug survival rate of 
etanercept was significantly higher than that of infliximab and 
adalimumab [26]. 
A recent study investigating the potential predictors of 
switching anti-TNF drugs in Korean patients with AS found 
that that 3 and 5 year drug survival rates were 52% and 48%, 
respectively, for infliximab, 62% and 42% for etanercept, and 
71% and 51% for adalimumab. A history of joint surgery and 
complete ankylosis of the sacroiliac joint was more frequent in 
switchers. A multivariate Cox’s proportional hazard analysis 
showed that the use of adalimumab as the first anti-TNF drug 
was less likely to lead to switching, and complete ankylosis of 
the sacroiliac joints was more likely to do so. The main reasons 
for switching were drug inefficacy and adverse events, but the 
differences in the clinical data of the patients in these two groups 
were not significant [27]. 
The national Swedish Biologics Registry (which is con-
nected with national population-based registers) has shown 
that the co-administration of conventional disease-modifying 
rheumatic drugs (cDMARDs) was associated with a better 5 
year retention of the first anti-TNF drug [28] in patients with 
a clinical diagnosis of AS or undifferentiated SpA who started 
treatment with adalimumab, etanercept, or infliximab as their 
first anti-TNF drug between 2003 and 2010. 
A retrospective analysis of the data from RADIUS 1 (a 5 year 
observational registry of patients with RA) designed to deter-
mine the time to the first and second course discontinuation of 
etanercept, infliximab, and adalimumab (first course therapy 
was defined as the first exposure to an anti-TNF drug, and 
second course therapy as exposure to an anti-TNF drug after 
the first discontinuation) found that the first and second course 
retention of anti-TNF drugs was similar, but there was less first 
course discontinuation due to adverse events with etanercept 
than with infliximab [29].
Finally, another retrospective study of AS patients treated 
with adalimumab, etanercept, or infliximab between 2000 and 
In the Norwegian registry, 30% percent of the 
ankylosing spondylitis patients switched  
to a second anti-tumor necrosis factor drug
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Akerman and co-authors tried to compare the lifetime risk of 
total hip replacement (THR) surgery for osteoarthritis between 
countries and over time. In 2003, lifetime risk of THR ranged 
from 8.7% (Denmark) to 15.9% (Norway) for females and 
from 6.3% (Denmark) to 8.6% (Finland) for males. With the 
exception of females in Norway (where lifetime risk started 
and remained high), lifetime risk of THR increased signiﬁcantly 
for both genders in all countries from 2003 to 2013. In 2013, 
lifetime risk of THR was as high as 1 in 7 women in Norway, 
and 1 in 10 men in Finland. Females consistently demonstrated 
the highest lifetime risk of THR at both time points. Notably, 
lifetime risk for females in Norway was approximately double 
the risk for males in 2003 (females 15.9%, 95% conﬁdence 
interval [95%CI] 15.6–16.1; males 6.9%, 95%CI 6.7–7.1), and 
2013 (females 16.0%, 95%CI 15.8–16.3; males 8.3%, 95%CI 
8.1–8.5). Using representative, population-based data, this 
study found statistically signiﬁcant increases in the lifetime risk 
of THR in ﬁve countries over a 10 year period, and substantial 
between-gender differences. These multinational risk estimates 
can inform resource planning for osteoarthritis service delivery.
Arthr Care & Res 2017; 69: 1659
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Lifetime risk of primary total hip replacement surgery for osteoarthritis from 2003 to 2013: a 
multinational analysis using national registry data
Capsule
“Nobody can be exactly like me. Sometimes even I have trouble doing it”
Tallulah Brockman Bankhead, (1902–1968), American screen and stage actress known for her husky voice, outrageous personality, 
and devastating wit
